Abstract

Background and Aims: Intestinal dysbiosis is implicated in the pathogenesis of Crohn’s disease (CD). We evaluated fecal and sera microbial markers for clinical use in detecting CD.Methods: Fecal samples from 346 Asian subjects were collected, including 95 patients with CD, 81 patients with ulcerative colitis (UC), 65 patients with irritable bowel syndrome (IBS), and 105 healthy subjects (HS). Microbial indicators Fusobacterium nucleatum (Fn), Faecalibacterium prausnitzii (Fp), and Escherichia coli (E. coli) were identified based on a review of the literature. The relative abundance of the three bacterial markers were measured by qPCR, and two serological microbial markers (anti-Fn, anti-E. coli) were measured by ELISA. We evaluated the diagnostic performance of these microbial markers by ROC curve analysis.Results: The quantification of Fp, Fn, and E. coli of fecal samples is relatively stable when stored up to 6 h at room temperature. The significant increasing abundances of Fn were accompanied by a decline of Fp in the CD group. Fn exhibited a slightly higher diagnostic value than Fp in distinguishing CD from HS (Area Under Curve, AUC = 0.841 vs. 0.811) or irritable bowel syndrome (IBS) groups (AUC = 0.767 vs. 0.658), and the further combination of Fn and Fp improved the diagnostic value (HS, AUC = 0.867; IBS, AUC = 0.771). However, anti-E. coli and anti-Fn antibodies in serum did not possess diagnostic value for CD or UC.Conclusion: A combination of fecal Fn and Fp was identified as a valuable marker for CD diagnosis. A CD bacterial marker panel may provide a simple non-invasive approach to screen for CD.

Highlights

  • The intestinal microbiome is a key factor in the development and maintenance of mucosal homeostasis (Sartor, 2015), and dysbiosis is closely involved in the pathogenesis of inflammatory bowel disease (IBD)

  • We investigated the abundance of Fusobacterium, Escherichia coli, and Faecalibacterium in published Crohn’s disease (CD) data sets

  • There were 27 studies related to microbial features of CD that were included in the analysis, and the 909 CD and 768 healthy subjects (HS) samples were collected in China, America, and Europe from 2006 to 2017

Read more

Summary

Introduction

The intestinal microbiome is a key factor in the development and maintenance of mucosal homeostasis (Sartor, 2015), and dysbiosis is closely involved in the pathogenesis of inflammatory bowel disease (IBD). Several bacterial species have been implicated in CD by direct detection or by disease-associated antimicrobial immune responses. Fusobacterium nucleatum (Fn)-associated dysbiosis was found in gastrointestinal disease, including colorectal cancer (CRC) and CD (Yu T.C. et al, 2017; Liu et al, 2018), and highly invasive strains of Fn were suggested to be useful biomarkers for IBD (Strauss et al, 2011). Intestinal dysbiosis is implicated in the pathogenesis of Crohn’s disease (CD). We evaluated fecal and sera microbial markers for clinical use in detecting CD

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call